Abstract
Optimal platelet inhibition is an important therapeutic adjunct in carotid artery stenting (CAS). We aimed to evaluate if the use of cilostazol among patients who underwent CAS would lead to any benefit on in-stent restenosis. We searched Pub Med and Cochrane through September 2015 for all the
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have